Details of the Drug

General Information of Drug (ID: DMPF5OX)

Drug Name
3PO
Synonyms
18550-98-6; 3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one; (E)-3PO; 13309-08-5; CHEMBL3105848; (E)-3-pyridin-3-yl-1-pyridin-4-ylprop-2-en-1-one; (E)-3-(Pyridin-3-yl)-1-(pyridin-4-yl)prop-2-en-1-one; SCHEMBL196639; 3-PO; (E)-3PO;3PO; CHEBI:144367; BCP34641; ZINC3997313; BDBM50445948; s7639; 3PO, >=98% (HPLC); AKOS025142053; CCG-266648; CS-5491; SB17190; NCGC00386709-03; AS-55969; HY-19824; AB00079158-01; SR-01000203323; SR-01000203323-1; 2-Propen-1-one, 3-(3-pyridinyl)-1-(4-pyridinyl)-; 3-(pyridin-3-yl)-1-(pyridin-4-yl)prop-2-en-1-one; (2E)-3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one; (E)-3-pyridin-3-yl-1-pyridin-4-ylprop-2-en-1-one (3PO); (2E)-3-(PYRIDIN-3-YL)-1-(PYRIDIN-4-YL)PROP-2-EN-1-ONE
Indication
Disease Entry ICD 11 Status REF
Pulmonary fibrosis CB03.4 Investigative [1]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 210.23
Logarithm of the Partition Coefficient (xlogp) 1.6
Rotatable Bond Count (rotbonds) 3
Hydrogen Bond Donor Count (hbonddonor) 0
Hydrogen Bond Acceptor Count (hbondacc) 3
Chemical Identifiers
Formula
C13H10N2O
IUPAC Name
(E)-3-pyridin-3-yl-1-pyridin-4-ylprop-2-en-1-one
Canonical SMILES
C1=CC(=CN=C1)/C=C/C(=O)C2=CC=NC=C2
InChI
InChI=1S/C13H10N2O/c16-13(12-5-8-14-9-6-12)4-3-11-2-1-7-15-10-11/h1-10H/b4-3+
InChIKey
UOWGYMNWMDNSTL-ONEGZZNKSA-N
Cross-matching ID
PubChem CID
5720233
ChEBI ID
CHEMBL3105848
TTD ID
D4RMB0
Drug-Molecule Activity Atlas (DMA)NEW Click to Jump to the Detailed DMA Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Renal carcinoma antigen NY-REN-56 (PFKFB3) TTTHMQJ F263_HUMAN Antagonist [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 PI3K-Akt-mTOR/PFKFB3 pathway mediated lung fibroblast aerobic glycolysis and collagen synthesis in lipopolysaccharide-induced pulmonary fibrosis. Lab Invest. 2020 Jun;100(6):801-811.
2 CPEB4 Increases Expression of PFKFB3 to Induce Glycolysis and Activate Mouse and Human Hepatic Stellate Cells, Promoting Liver Fibrosis. Gastroenterology. 2020 Jul;159(1):273-288.